newsfilter
← Latest News
Business Wire·

Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress

Core royalty platform on track; receiving GSK royalties of $61.9 million Achieved net product revenues of $19.1 million, representing 66% year-over-year growth driven by launch of XACDURO® and growth of key core